Jean-francois F. Rossi

Avignon, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers.

Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers.

Journal: Frontiers in immunology
Published: November 18, 2025

Is the MAPK ERK5 the nexus from FAO to NK cell-mediated metastasis immune surveillance?

Is the MAPK ERK5 the nexus from FAO to NK cell-mediated metastasis immune surveillance?

Journal: Frontiers in immunology
Published: June 05, 2025

Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer.

Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer.

Journal: Cancer biology & medicine
Published: February 06, 2024

Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study.

Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study.

Journal: Vaccines
Published: January 25, 2023

Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.

Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.

Journal: Frontiers in immunology
Published: May 09, 2022

Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19.

Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19.

Journal: Drugs in context
Published: January 04, 2022

Tocilizumab in Treatment for Patients With COVID-19.

Tocilizumab in Treatment for Patients With COVID-19.

Journal: JAMA internal medicine
Published: April 05, 2021

Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer.

Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer.

Journal: Frontiers in immunology
Published: August 17, 2020

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.

Journal: British journal of haematology
Published: July 17, 2020

The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.

The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.

Journal: Drugs in context
Published: January 10, 2020

Polyoxidonium® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer.

Polyoxidonium® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer.

Journal: Frontiers in immunology
Published: July 09, 2019

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Journal: Leukemia
Published: November 22, 2018
Showing 1-12 of 28

Last Updated: 09/26/2026